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Background: To compare life span of persons with and without ocular pseudoexfoliation syndrome (PES).
Methods: The study is based on an epidemiological survey conducted in Sør-Trøndelag county, Norway, in
1985–86. All inhabitants over 64 years of age (2109 individuals) were invited. Mortality information was obtained
from The Norwegian Institute of Public Health in 2014, by which time 99% of the participants were deceased.
Results:When adjusting for age and gender, life spanwas not statistically different in personswith andwithout PES.
Following the diagnosis of PES, patients' survival was up to, and beyond, 30 years.
Conclusions:Our observations suggest that, despite all the systemic aberrations reported in persons with ocular PES,
none or only marginal functional changes are caused in extraocular organs and tissues. The present study supports
the notion that systemic PES is not a life-threatening condition.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The classical ﬁnding of the pseudoexfoliation syndrome (PES) in the
eye, as observed by slit-lamp examination, is characterized by a gray,
granular material on the anterior lens surface and along the pupillary
border. The ﬁrst description (Lindberg, 1989) was followed by
numerous clinical and morphological studies of the various ocular
aspects of the condition over the following decades. For almost sixty
years, PESwas regarded as being a purely intraocular diseasewith capsu-
lar glaucoma as one of the complications in a proportion of patients.
The view of PES being a purely intraocular diseasewas challenged by
the discovery that the intraocular deposits have their counterparts in
various extraocular connective tissues (Ringvold, 1973a; Ritch and
Schlötzer-Schrehardt, 2001). PES was subsequently perceived as a
connective tissue disorder, whereby the PE-subunits consist of a core
protein of aberrant elastic microﬁbrills (Ringvold, 1973b; Streeten et al.,
1986; Thorleifsson et al., 2007) surrounded by various glycoconjugates
(Davanger, 1978; Huﬂejt et al., 2014; Konstas et al., 1990). However, it
should be mentioned that immunohistochemical analysis has indicated
differences in the carbohydrate composition between intra- and
extraocular PE deposits (Hietanen et al., 1995).logy, Ullevaal, Oslo University
edal).
. This is an open access article underClinically, a number of observations indicate that PESmayhave func-
tional implications beyond the eye (Bettis et al., 2014; Katsi et al., 2013;
Tarkkanen et al., 2008), although opinion is divided with regards to its
signiﬁcance (Andrikopoulos et al., 2014; Gonen et al., 2013; Hietanen
et al., 2002; Ringvold, 2001; Schumacher et al., 2001; Tarkkanen,
2008). Recently, the association between ocular PES and vascular dis-
ease has been evaluated in a meta-analysis based on sixteen epidemio-
logic studies (Wang et al., 2014). The authors listed a number of
limitations in the included papers while concluding that, overall, the
current literature suggests that PES is associated with increased risk of
vascular disease. Despite this and numerous morphological, biochemi-
cal, genetic, and clinical observations, the question of whether or not
PES generates systemic disease, has still not been concluded.
A different approach to evaluate the relationship between PES and
possible systemic effects is to study mortality. In general, serious sys-
temic disorders are likely to inﬂuence life expectancy. Previous studies
have not showed any association between PES and overall mortality
(Grødum et al., 2004; Ringvold et al., 1997; Ritland et al., 2004; Shrum
et al., 2000; Svensson and Ekström, 2014; Tarkkanen and Kivelä,
2014). If PES has no effect on mortality, affected people will, in general,
reach or exceed life expectancy. Interestingly, our study from 1997 indi-
cated “personswith ocular PES are older than thosewithout.” This result
was obtained 12 years after the initial examination — with 52% of the
participants having died. The present study is a follow-up study, com-
paring the life span of PES-positive and PES-negative persons, 29 years
following the initial observation of PES.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
PES prevalence in 3 different municipalities in Sør-Trøndelag county, Norway. Examina-
tion was performed in 1985–86, and 1888 of 2109 persons above 64 years of age were
examined.
Age groups (years) PES-negative PES-positive Total
65–69 447 (89.0%) 55 (11.0%) 502 (100%)
70–74 482 (87.2%) 71 (12.8%) 553 (100%)
75–79 337 (81.6%) 76 (18.4%) 413 (100%)
80–84 193 (76.0%) 61 (24.0%) 254 (100%)
85–89 81 (68.6%) 37 (31.4%) 118 (100%)
90–98 29 (60.4%) 19 (39.6%) 48 (100%)
Total 1569 (83.1%) 319 (16.9%) 1888 (100%)
Fig. 1. Bar chart showing median life length in PES-negative and PES-positive age groups
by 01.10.2014, i.e. 29 years after examination. The differences are not statistically
signiﬁcant.
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This study has been based on ﬁgures from the epidemiological
survey conducted in three municipalities (Hitra, Holtålen, Rennebu) in
the county of Sør-Trøndelag, Norway in 1985–86 (Ringvold et al.,
1988). All inhabitants above 64 years of age were invited (2109
persons), 1888 (1018 women, 870 men) were examined, while 221
had chosennot to participate. Informed consentwas obtained according
to the Helsinki declaration. Conventional slit-lamp examination was
performed on a dilated pupil to examine for PES. Due to various ocular
diseases (corneal opacities, enucleation, etc.) 43 persons had only one
eye examined. “PES-positive” indicated PES in at least one eye.
After approval from the Regional Ethical Committee, mortality
informationwas obtained fromTheNorwegian Institute of Public Health;
As at 01.10.14, all of the 2109 individualswere registered as being alive or
deceased. Where appropriate, date of death was documented.
3. Statistical analysis
Results on continuous variables are presented as means and
standard deviations, or as medians when appropriate. Results on cate-
gorical variables are presented as numbers and percentages.
For the comparison of mean age in two groups, an independent
samples t-test was employed, while a chi-square test was used to com-
pare percentages.
Cox regression analysis was used for the analysis of the association
between PES (yes vs. no) and mortality, with adjustment for gender
and age. Results from this analysis are presented as hazard ratios with
95% conﬁdence intervals and p-values.
Cox regression analysis is also used when comparing the mortality
among those who participated in the study with those who were not
willing to participate.
The proportional hazard assumptions of the Cox regression analysis
was checked for both of these models and found to be adequately met.
This assumption was checked by visual inspection of the log–log
Kaplan–Meier curves for the groups deﬁned by the independent
variables in the models. For each variable in each model the distances
between the log–log curves were found to be constant over time.
In order to compare the mortality pattern among the participants
with PES with the corresponding mortality pattern during the same
time interval among the inhabitants in the Sør-Trøndelag county
(306197 inhabitants by 01.01.2014), we calculated the standardized
mortality ratio for these two populations, with 95% conﬁdence interval.
A signiﬁcance level of 5% was used. The statistical analysis was
performed by using the software program IBM-SPSS version 20.
4. Results
The clinical screening was conducted in 1985–86. Patient life span
was assessed as at 01.10.2014. Of the 1888 examined and 221 not-
examined individuals, 98.6% and 98.8% respectively, were deceased by
this time.
4.1. Concerning the 1888 examined persons
PES was found in 319 people (16.9%). The prevalence was signiﬁ-
cantly higher in females than males (19.1% vs. 14.4%; Pearson's chi-
square test; p = 0.007), and increased markedly with age (Pearson's
chi-square test; p b 0.001), from 11% in the lowest age group to 39% in
the highest (Table 1). The collective mean age of both PES positive and
negative groups at the time of examination was 74.5 years (range
65–98 years), signiﬁcantly higher among PES-positive group (77.2 vs.
74.0 years; independent samples t-test; p b 0.001). The relative risk of
death when comparing participants with and without PES (reference
group) was 1.01 (95% CI: 0.89–1.13; Cox regression analysis; p =
0.932), age and gender adjusted.As shown in Fig. 1, median life span as at 01.10.2014 was similar
among participants with and without PES, regardless of age at time of
observation.
The survival function of PES-positive and PES-negative persons in
the age group 65–69 years is shown in Fig. 2a. Similar curves were
found in the other age groups, and the differences between the two
curves were not statistically signiﬁcant in any of the age groups (Fig.
2b-f).
When comparing the mortality pattern from 1985–86 to 2014
among the 319 PES-positive persons with the corresponding pattern
in the population above 64 years of age from the whole county of Sør-
Trøndelag, a standardized mortality ratio of 0.98 (95% CI: 0.88–1.09)
was found.
In total, 55 PES-positive cases were identiﬁed in the 65–69 years old
group, of which 21 persons were PES-positive for more than 20 years
before their death. Interestingly, one PES-positive person in this group
was still alive on 01.03.15 (97 years old), i.e. 30 years after the diagnosis
of PES was made.
4.2. Concerning the 221 not-examined persons
Mean age at time of invitation (i.e. 1985–86)was 76.6 (SD 7.1) years
in not-examined individuals versus 74.5 (SD 6.5) years in the examined
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pendent samples t-test; p b 0.001). Regardless of the presence of PES,
the relative risk of death, when comparing inhabitants who
participated with those who did not (reference group), was 0.79 (95%
CI: 0.69–0.91), after adjustment for age and gender.
The life span of the 1888 participants versus the 221 non-participants
at 01.10.2014 is shown in Fig. 3. Median life span was slightly reduced in
the two youngest, non-participating groups (65–69 years; Mann–
Whitney test; p = 0.030, and 70–74 years; p = 0.023), whereas the
remaining 4 groups showed no difference. The two youngest groups,a
c
Fig. 2. Kaplan–Meier plots showing survival function of PES-negative and PES-positive perso
(e) 85–89 years, and (f) 90–98 years at time of examination (1985–1986). n denotes the numb
are not statistically signiﬁcant.PES-positive and PES-negative collectively, consisted of 44 and 46
persons, respectively.
5. Discussion
According to previous studies, mortality is not increased in PES-
positive people (Grødum et al., 2004; Ringvold et al., 1997; Ritland
et al., 2004; Shrum et al., 2000; Svensson and Ekström, 2014). The aim
of the present study was to compare the life span of PES-positive to
PES-negative persons. No differences were found between the twob
d
ns in the age groups (a) 65–69 years, (b) 70–74 years, (c) 75–79 years, (d) 80–84 years,
er of persons at risk at the time points indicated. The differences between the two curves
ef
Fig. 2 (continued).
Fig. 3. Bar chart showing median life length in 221 not-examined persons (blue) versus
1888 examined persons (green) by 01.10.2014, i.e. 29 years after the ﬁles were collected.
The two youngest age groups of the not-examined population (65–69; p b 0.03, and
70–74; p b 0.023) showed slightly reduced life length.
768 J.K. Slettedal et al. / EBioMedicine 2 (2015) 765–769groups. This ﬁnding was supported by standardized mortality ratio
analysis, comparing PES-positive persons with the population of the
Norwegian county Sør-Trøndelag.
A different approach to elucidating this issue is to evaluate how long
PES-positive persons actually stay alive after debut of the syndrome.
Few PES-positive cases were found below 69 years of age in the area
surveyed (Table 1). Fig. 1 demonstrates that a number of PES-positive
persons in the youngest group (65–69 years) survived at least 20 years
after diagnosis. Furthermore, the survival functions in PES-positive and
PES-negative persons turned out to be similar (Fig. 2).PES probably had no impact on life span in the examined population
(1888 individuals). With regards to the 221 non-participants (Fig. 3),
the slightly reduced life span in the two youngest groups may indicate
increased morbidity. Assuming that the PES prevalence pattern is
similar among the examined and not-examined persons, i.e. increasing
with age, it is noteworthy that reduced life span in the not-examined
population is conﬁned to the two youngest age groups with the lowest
PES-positive numbers, whereas the remaining four age groups, with
signiﬁcantly higher PES prevalence, showed normal life span. It can be
concluded, therefore, that PES is not responsible for a reduced life span.
Taken together, these observations (normal life span along with
normal mortality rates in PES-positive people) seem to be inconsistent
with most of the recent literature for two reasons:
1) A large number of studies have been presented indicating impaired
circulation in various tissues and vital organs in persons with PES
(Akarsu and Ünal, 2005; Atalar et al., 2006; Andrikopoulos et al.,
2014; Cumurcu et al., 2013; Djordjevic-Jocic et al., 2012; French
et al., 2012; Gonen et al., 2013; Katsi et al., 2013; Mitchell et al.,
1997; Praveen et al., 2011; Turacli et al.;, 2007; Visontai et al.,
2008). It is unlikely that increased prevalence of serious diseases,
like heart attack and stroke, would not inﬂuence mortality and life
span. Importantly, it should also be added that, although most
reports indicate compromised circulation in PES-positive people,
some showed no difference (Tarkkanen et al., 2008).
2) Hyperhomocysteinemia in PES-positive persons has been conﬁrmed
(Leibovitch et al., 2003; Vessani et al., 2003). In addition, it has been
shown that plasma homocysteine levels correlate directly with the
prevalence of various arterial occlusive diseases (Boushey et al.,
1995; Konecky et al., 1997). Furthermore, there is an association be-
tween raised plasma concentration of homocysteine and long-term
mortality in patients with coronary artery disease (Martín-Herrero
et al., 2007), and also between hyperhomocysteinema and stroke
(Hankey and Eikelboom, 2001). Consequently, the reported
hyperhomocysteinemia in PES-positive individuals should tend to
increase mortality and reduce life span.
The ﬁnding that PES had no effect on life span does not necessarily
mean that PES has no effect on cause of death. In fact, PES could cause
increased vascular-related mortality if it reduced other causes of
death. Moreover, our ﬁndings only apply to the population studied,
and we cannot exclude a different result in populations with different
769J.K. Slettedal et al. / EBioMedicine 2 (2015) 765–769genetic background. Furthermore, these ﬁndings only apply to persons
that were older than 64 years at enrollment of the study. As the
prevalence of pseudoexfoliation increases with age, new cases of
pseudoexfoliation may appear in all groups in our material.
The association between PES and a number of systemic diseases listed
above is noteworthy. However, despite all the reported pathological aber-
rations in PES-positive persons, none or only marginal functional changes
are induced by PES in extraocular organs and tissues. It is also noteworthy
that PES-positive people can live up to and beyond 30 years following
their diagnosis. We conclude that systemic PES is not a life threatening
condition, as PES-positive persons do not seem to die from, but rather
with this disorder.
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